Drugs / VRC-EBOADC069-00-VP
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02408913 | Mar 2015 → Apr 2017 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02368119 | Mar 2015 → Sep 2016 | Ebola hemorrhagic fever | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 1 | NCT02231866 | Aug 2014 → Apr 2017 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC-EBOADC069-00-VP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02408913 ↗ |
| Known as | cAd3-EBO | “VRC-EBOADC069-00-VP (cAd3-EBO) is composed of two recombinant cAd3 vectors in a 1:1 ratio that express Ebola WT GPs from Zaire and Sudan strains.” NCT02231866 ↗2“The vaccine is a recombinant chimpanzee adenovirus Type 3-vectored Ebolavirus vaccine (cAd3-EBO), VRC-EBOADC069-00-VP.” NCT02368119 ↗ “VRC-EBOADC069-00-VP (cAd3-EBO)” NCT02408913 ↗ |
| Modality | Vaccine | “cAd3-EBO Ebola Chimpanzee Adenovirus Vector Vaccine GP Zaire + GP Sudan” NCT02231866 ↗ |
| Route | Intramuscular | “administered as single intramuscular (IM) injections” NCT02231866 ↗ |